SCHEMBL5534183

SCHEMBL5534183

Cc1ccc(CNC(=O)c2nc3n(c(=O)c2O)CC(=O)N3)cc1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
KCNH2 Q12809 1/20 0.39
CYP2C9 P11712 1/20 0.39
NR1H4 Q96RI1 1/20 0.37
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
RAB9A P51151 1/20 0.36
WDR5 P61964 1/20 0.36
MMP13 P45452 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539177 0.91 MMP13 (0.47) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL5647057 0.86 CNR1 (0.42) KMT2AMEN1TSHRWDR5
SCHEMBL5643186 0.84 KCNH2 (0.50) NPC1KCNH2CYP2C9KCNE1CCR1
SCHEMBL5538310 0.83 KCNH2 (0.39) KCNH2CYP2C9WDR5MMP13
SCHEMBL5538264 0.82 MMP13 (0.45) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL5538434 0.80 KCNH2 (0.40) NPC1KCNH2CYP2C9NR1H4KCNE1
SCHEMBL5536084 0.78 TSHR (0.48) NPC1KCNH2CYP2C9KMT2ALMNA
SCHEMBL3842530 0.77 KCNH2 (0.42) NPC1KCNH2CYP2C9NR1H4KMT2A
SCHEMBL5535512 0.77 MMP13 (0.44) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917364 0.77 NPC1 (0.39) NPC1KCNH2CYP2C9NR1H4KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753767-A1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-02-21 EP claimed
WO-2005118589-A1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-15 WO claimed
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US claimed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors CCNI, TOP1, APOBEC3C NPC1 729/4885KCNH2 3080/4885CYP2C9 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.